Aerie Pharmaceuticals Announces Voting Results of 2014 Annual Meeting of Stockholders

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, announced voting results from the Company's Annual Meeting of Stockholders, which was held earlier today. Approximately 74 percent of outstanding shares were represented at the meeting.

Director nominees Vicente Anido Jr., Ph.D., and David W. Gryska were re-elected to Aerie’s Board of Directors. The Company also is announcing separately today that James Mazzo, former head of Abbott Medical Optics, has been elected to Aerie’s Board. In addition, with the expiration of her Board term, Janet L. Conway, Ph.D., has stepped down as director. With these Board changes, Aerie currently has eight directors.

Furthermore, Aerie’s shareholders ratified PricewaterhouseCoopers, LLP, as Aerie’s independent registered accounting firm for the fiscal year ending December 31, 2014.

“It is a great privilege to participate in Aerie’s first annual stockholders’ meeting,” commented Vicente Anido, Jr., Ph.D., CEO and Chairman of the Board of Aerie Pharmaceuticals. "Further, on behalf of the entire Board, I wish to thank Janet Conway for her service to the Company and for having been an integral part of our progress to date."

Final voting results of Aerie’s 2014 Annual Meeting of Stockholders are available in a current report on Form 8-K that has been filed with the U.S. Securities and Exchange Commission today.

About Aerie Pharmaceuticals

Aerie is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies. The Company is preparing for two Phase 3 registration trials in the U.S. where the primary efficacy endpoint will be to demonstrate non-inferiority of IOP lowering for Rhopressa™ (dosed once daily and twice daily) compared to timolol (dosed twice daily), along with a third safety-only trial in Canada. The Company is also currently executing a Phase 2b clinical trial where the primary efficacy endpoint is to demonstrate superiority of Roclatan™ to each of its components.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the success, timing and cost of our ongoing and anticipated preclinical studies and clinical trials for our current product candidates, including statements regarding the timing of initiation and completion of the studies and trials; our expectations regarding the clinical effectiveness of our product candidates and results of our clinical trials; the timing of and our ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, our product candidates; our expectations related to the use of proceeds from our initial public offering; our estimates regarding anticipated capital requirements and our needs for additional financing; the potential advantages of our product candidates; and our ability to protect our proprietary technology and enforce our intellectual property rights. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and industry change, and depend on regulatory approvals and economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. We discuss many of these risks in greater detail under the heading "Risk Factors" in the quarterly and annual reports that we file with the Securities and Exchange Commission (SEC). Forward-looking statements are not guarantees of future performance and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.